News
Researchers examine ageing brain with new level of imaging detail

Two researchers from The University of Texas at Dallas’ Center for Vital Longevity (CVL) have received a five-year grant from the National Institutes of Health (NIH) to expand their study of brain structure, function and cognition across time through the use of powerful high-resolution imaging.
Psychology professors Dr. Kristen Kennedy and Dr. Karen Rodrigue in the School of Behavioral and Brain Sciences were awarded $3.7 million from the NIH’s National Institute on Aging to extend their Dallas Area Longitudinal Lifespan Aging Study to include a fourth and fifth wave of data collection, which will allow them to follow study participants across 14 years.#
The project already spans three cycles of data collection over approximately eight years, with individuals ranging in age from 20 to 98.
Kennedy and Rodrigue will use one of the most powerful imaging machines in existence — the 7-Tesla magnetic resonance scanner, one of about 35 in the U.S., at the Advanced Imaging Research Center (AIRC), a joint facility with UT Southwestern Medical Center, UT Dallas and other North Texas institutions.
Using this 24-ton MRI machine that has the ability to image less than a millimeter of tissue, the researchers will be able to explore the chemical metabolites of the brain’s tissue.
Kennedy, director of the Neuroimaging of Aging and Cognition Lab at CVL.
The researcher said: “Understanding the mechanisms behind normal versus pathological ageing is a crucial public health goal.
“While cognitive neuroscience has made great strides in identifying the major brain differences between younger and older adults, a true measure of ageing requires longitudinal studies like ours that show how brain and cognitive metrics change over time within an individual, while also sampling individuals in middle adulthood.”
By project’s end, the researchers will have five waves of data spanning 180 study participants.
Rodrigue, director of the Cognitive Neuroscience of Aging Lab at CVL.
She said: “The next two sets of data will add novel information about the metabolic factors that may determine if a person’s brain-ageing trajectory is healthy or not, leading to pathologies such as Alzheimer’s disease.”
Technological advances since the research began have enabled scientists to study ageing at a more granular level as they look for biomarkers that advance understanding of individual differences in brain ageing.
Kennedy said: “The biological interactions that determine how we age are beyond the reach of traditional neuroimaging,.
“These neurocognitive trajectories and outcomes must be studied at the micro-, meso- and macroscales: from cells and molecules to the tissue level that we can now see at 7-Tesla, to the larger level that we have been observing with traditional MRI resolution.”
The new phase of the project has three aims. The first involves seeking microlevel chemical factors in larger-scale brain changes over time.
Kennedy said: “We believe that participants who maintain previous levels of blood-oxygen signals will differ in their neurometabolite signatures from those who don’t.
““Whether that comes in the form of high antioxidant levels, lower inflammation or other factors that we can now measure — that’s what we’re out to learn.”
The second aim involves measuring cortical-layer thickness and myelin content to identify patterns that correspond with healthy or dysfunctional ageing.
The final aim is to begin untangling the relationships between ageing at the three scale levels.
The 7-T imaging will allow for three new types of imaging precision for the CVL project: Myelin can be measured to gauge the health of white matter connections between brain regions; cortical thickness can be measured with greater precision to gain new insight into how the cerebral cortex ages; and neurochemical molecular and cellular brain signatures can be identified that may tie strongly to certain ageing patterns.
Kennedy said: “We will measure regional brain concentrations of several neurometabolites, including antioxidants like glutathione, the neurotransmitters gamma-aminobutyric acid (GABA) and glutamate, neuroinflammation markers, additional amino acids and more.
“This opportunity to bridge gaps in knowledge between fields and across spatial scales is immensely exciting.”
Rodrigue emphasised that major advances in the study of ageing are only possible with long-term, longitudinal studies, which by design must span multiple funding awards.
She said: “With this continuing support from NIH, we can now test hypotheses about the health biomarkers and the specific patterns of brain ageing that combine to predict successful cognitive ageing in older adulthood, as well as those patterns that underlie the progression from healthy to pathological ageing.”
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.













